2-溴甲基-1,3-苯并噻唑 | 106086-78-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-溴甲基-1,3-苯并噻唑
• 中文别名: 2-(溴甲基)苯并噻唑
• 英文名称: 2-(bromomethyl)-1,3-benzothiazole
• 英文别名: 2-bromomethyl-benzothiazole；2-(bromomethyl)benzo[d]thiazole
• CAS: 106086-78-6
• 化学式: C₈H₆BrNS
• mdl: MFCD00461195
• 分子量: 228.112
• InChiKey: WFLCAOGKZQTOIG-UHFFFAOYSA-N

物化性质

• 熔点：
  47 °C
• 沸点：
  288℃
• 密度：
  1.680
• 闪点：
  128℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 危险类别码：
  R34
• 危险品运输编号：
  UN 3261
• 海关编码：
  2934999090
• 包装等级：
  III
• 危险类别：
  8
• 安全说明：
  S26,S36/37/39,S45
• 危险标志：
  GHS05,GHS07
• 危险性描述：
  H302,H315,H318,H335
• 危险性防范说明：
  P261,P280,P305 + P351 + P338
• 储存条件：
  2-8°C

SDS

Name:	2-(Bromomethyl)-1 3-benzothiazole 95+% Material Safety Data Sheet
Synonym:
CAS:	106086-78-6

Section 1 - Chemical Product MSDS Name:2-(Bromomethyl)-1 3-benzothiazole 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
106086-78-6	2-(Bromomethyl)-1,3-benzothiazole	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 106086-78-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 49 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6BrNS
Molecular Weight: 228

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 106086-78-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(Bromomethyl)-1,3-benzothiazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 106086-78-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 106086-78-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 106086-78-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴甲基-1,3-苯并噻唑 生成 2-(2-methyl-but-1-enyl)-benzothiazole
  参考文献：
  名称：

  693.通过霍纳反应合成杂环烯烃

  摘要：

  DOI：

  10.1039/jr9650003793
• 作为产物：
  描述：

  2-甲基苯并噻唑 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 以61%的产率得到2-溴甲基-1,3-苯并噻唑
  参考文献：
  名称：

  通过强效 GFP 成像兼容光开关试剂 SBTubA4P 和 SBTub2M 对微管动力学和完整性、迁移和有丝分裂进行体内光控制

  摘要：

  光开关试剂是细胞生物学高精度研究的强大工具。当这些试剂在二维 (2D) 细胞培养物中全局施用但局部光激活时，它们可以发挥微米和毫秒级的生物控制作用。这使得它们在生物学上更相关的三维（3D）模型和体内具有巨大的应用潜力，特别是对于研究具有固有时空复杂性的系统，例如细胞骨架。然而，由于典型成像条件下的光开关异构化、代谢缺陷以及有效浓度下水溶性不足的综合作用，光开关试剂解决胞质蛋白靶标的体内潜力在很大程度上仍未实现。在这里，我们优化了基于苯乙烯基苯并噻唑 (SBT) 支架的代谢稳定、类药秋水仙素微管抑制剂的效力和溶解度，该支架对典型的荧光蛋白成像波长无响应，因此能够进行多通道成像研究。我们在一种和两种蛋白质成像实验中将这些试剂应用于 3D 类器官和组织外植体以及经典模型生物（斑马鱼、爪蛙），其中时空局部照明使它们能够光控制微管动力学、网络结构和微管。具有细胞精度和秒级分辨率的体内依赖过程。这些纳

  DOI：

  10.1021/jacs.2c01020

文献信息

• Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist
  申请人：SmithKline Beecham Corporation

  公开号：US05977101A1

  公开（公告）日：1999-11-02

  Vitronectin receptor antagonists having the formula: ##STR1## which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.

  Vitronectin受体拮抗剂的化学式为：##STR1##，可用于治疗炎症、癌症和心血管疾病，如动脉粥样硬化和再狭窄，以及骨吸收是因素的疾病，如骨质疏松症。
• [EN] TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS<br/>[FR] TRAITEMENT OU PROPHYLAXIE D'ÉTATS PROLIFÉRATIFS
  申请人：UNIV DUNDEE

  公开号：WO2010125350A1

  公开（公告）日：2010-11-04

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  该发明涉及用于治疗或预防癌症和其他增殖性疾病的新化合物，例如这些疾病的特征是细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变体。该发明还提供包含一种或多种此类化合物的药物组合物，用于医学治疗，例如用于治疗或预防癌症或其他增殖性疾病，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。该发明还提供用于识别用于治疗或预防癌症和其他增殖性疾病的新化合物的方法，例如这些疾病的特征是细胞表达CYP1B1及其等位基因变体。该发明还提供一种用于确定该发明中化合物治疗癌症的疗效的方法。
• 一种BuChE-IDO1抑制剂、制备方法及其应用
  申请人：西南大学

  公开号：CN112694472A

  公开（公告）日：2021-04-23

  本发明涉及医药领域，具体公开了一种BuChE‑IDO1抑制剂、制备方法及其应用。本发明对舍他康唑的7‑氯‑3‑取代苯并噻吩部分进行了化学修饰，探究其对AChE，BuChE和IDO1的体外抑制活性的影响，并进一步的优化出本发明的目标化合物，解决了现有BuChE‑IDO1抑制剂针对性和安全性欠佳的技术问题。本发明探究出了在2‑苯并噻唑环上引入合适的取代基可以与周围的氨基酸和血红素铁形成额外的相互作用，从而增加类似物与BuChE和IDO1的结合亲和力，为更加高效、更具针对性的治疗晚期AD疾病拓宽了新思路。
• [1,3]-Claisen Rearrangement via Removable Functional Group Mediated Radical Stabilization
  作者：Md Nirshad Alam、Soumya Ranjan Dash、Anirban Mukherjee、Satish Pandole、Udaya Kiran Marelli、Kumar Vanka、Pradip Maity

  DOI：10.1021/acs.orglett.0c04109

  日期：2021.2.5

  A thermal O-to-C [1,3]-rearrangement of α-hydroxy acid derived enol ethers was achieved under mild conditions. The 2-aminothiophenol protection of carboxylic acids facilitates formation of the [1,3] precursor and its thermal rearrangement via stabilization of a radical intermediate. Experimental and theoretical evidence for dissociative radical pair formation, its captodative stability via aminothiophenol

  在温和条件下实现了α-羟酸衍生的烯醇醚的O-C到[1,3] -C热重排。羧酸的2-氨基硫酚保护通过自由基中间体的稳定化促进[1,3]前体的形成及其热重排。给出了解离自由基对的形成，其通过氨基硫酚的capdodative稳定性和独特的溶剂效应的实验和理论证据。氨基硫酚被脱保护以免受重排产物的影响，以及在衍生为有用的合成子后也被脱保护。
• Inhibition of the Cysteine Protease Human Cathepsin L by Triazine Nitriles: Amide⋅⋅⋅Heteroarene π-Stacking Interactions and Chalcogen Bonding in the S3 Pocket
  作者：Maude Giroud、Jakov Ivkovic、Mara Martignoni、Marianne Fleuti、Nils Trapp、Wolfgang Haap、Andreas Kuglstatter、Jörg Benz、Bernd Kuhn、Tanja Schirmeister、François Diederich

  DOI：10.1002/cmdc.201600563

  日期：2017.2.3

  We report an extensive “heteroarene scan” of triazine nitrile ligands of the cysteine protease human cathepsin L (hCatL) to investigate π‐stacking on the peptide amide bond Gly67–Gly68 at the entrance of the S3 pocket. This heteroarene⋅⋅⋅peptide bond stacking was supported by a co‐crystal structure of an imidazopyridine ligand with hCatL. Inhibitory constants (Ki) are strongly influenced by the diverse

  我们报道了半胱氨酸蛋白酶人组织蛋白酶L（hCatL）的三嗪腈配体的广泛的“杂芳烃扫描”，以研究S3口袋入口处的肽酰胺键Gly67–Gly68上的π堆积。杂芳基·····肽键的堆叠由咪唑并吡啶配体与hCatL的共晶体结构支持。抑制常数（ķ我）受到杂环的多样性和与S3口袋局部环境的特定相互作用的强烈影响。结合亲和力变化三个数量级。与烃类似物相比，所有杂芳族配体均具有增强的结合力。从杂芳烃和肽键的局部偶极矩的方向预测的能量贡献无法得到证实。分子间的C-S⋅⋅⋅O= C相互作用（硫族元素键）与Asn66的主链C = O增强了苯并噻吩基（K i = 4 n m）和苯并噻唑基（K i = 17 n m）配体的结合。 S3口袋。还测试了配体的相关酶罗德沙星。